Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2–P3 α-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach
Ikechukwu Achilonu, Emmanuel Amarachi Iwuchukwu, Okechinyere Achilonu, Manuel A. Fernandes, Yasien Sayed
Topics & Concepts
In silicoDrug discoveryPharmacologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)DrugDrug repositioningComputational biologyMedicineCoronavirus disease 2019 (COVID-19)ChemistryBiologyInternal medicineBiochemistryGeneDiseaseInfectious disease (medical specialty)Computational Drug Discovery MethodsSynthesis and biological activitySARS-CoV-2 and COVID-19 Research